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Introduction
An infection may be treated by one of several antibiotics to which the causative organism is sensitive. However, the choice of an antibiotic is based not only on susceptibility, but also on the killing capacity of the antibiotic, its rapidity of action, pharmacokinetics (adequate concentration at the infection site), toxicity and cost. The clinical microbiologist should, therefore, advise the treating doctor on the most appropriate antibiotic for his patient. However, in Sudan, serious limitations prevent microbiologists and clinicians from choosing the appropriate antibiotics. The Sudanese antibiotic formulary is deficient in essential injectable antibiotics necessary for the treatment of common and serious infections. Instead, the antibiotic formulary is overwhelmed by several brands and classes of injectable cephalosporins. Therefore, in the absence of specific antibiotics to treat common infections, clinicians have no choice, but to use variable brands of the widely available cephalosporins, probably unaware of the serious implications of the overuse of third generation cephalosporins (oxyimino cephalosporins). Highlighted in this article are the undesirable effects (collateral damage) associated with the overreliance on third generation cephalosporins, identify gaps in Sudan"s antibiotic formulary and recommend measures to ensure appropriate use of proposed additions to the formulary. . Cloxacillin /flucloxacillin is the ideal agent for treating infections with MSSA. It is the most effective agent against Staphylococcus aureus, having a minimum inhibitory concentration (MIC) of 0.25 mg/l, lower than any other antibiotic. It is well tolerated and up to 12 grams/day may be administered in the treatment of infective endocarditis. Having high bactericidal capacity, rapid action and narrow spectrum of activity, cloxacillin provides good killing capacity with minimum collateral damage (13) . Ampiclox, which is often used in Sudan for treating staphylococcal infections, is not an alternative to cloxacillin. It is a combination of two penicillins, not known to be synergistic or even additive, since both compounds compete for the same binding site (penicillinbinding protein). Furthermore, high doses of cloxacillin are often needed to treat serious staphylococcal infections, which mean that an equal amount of amoxicillin must be given along with cloxacillin that may be associated with unwanted effects. Methicillin resistant Staphylococcus aureus accounts for 50% to 60% of clinical isolates in our hospitals (11) . This is comparable to the prevalence of MRSA in neighbouring Arab countries. Shibl et al reported 32% in Kuwait, 52% in Oman and 60% in Egypt (14) . Lapse of infection control practice could have contributed to the high prevalence of MRSA in these countries. MRSA infection is treated with vancomycin. However, vancomycin is a pharmacodynamicaly inefficient antibiotic and is slow acting (15) . . However, in Sudan, we do not know the incidence of invasive pneumococcal disease or the prevalence of penicillin-resistant Streptococcus pneumoniae because of difficulties in performing culture and MICs for Streptococcus pneumoniae, due to lack of appropriate culture media. Until we resolve this problem and judging from the level of resistance among Streptococcus pneumoniae in the neighbouring countries and elsewhere, we advise our clinicians not to treat pneumococcal meningitis with penicillin. While respiratory and bloodstream infections with pneumococci showing low to moderate level resistance may respond to high doses of penicillin or ampicillin, meningitis treatment failures have been documented in infections with even low level penicillin-resistant strains. Therefore, initial treatment of meningitis should include high dose of cefotaxime or ceftriaxone with vancomycin (26) . This is one of the few situations where the use of a third generation cephalosporin is justified. β-haemolytic Streptococci belongs to a wide range of microorganisms that cause a variety of infections. Soft tissue infection with Streptococcus pyogenes, with or without Staphylococcus aureus may progress to necrotizing fasciitis, an infection with high morbidity and mortality. These organisms may also produce toxic shock syndrome toxin that adds insult to injury. Clindamycin is an essential additive to penicillin/flucloxacillin in the treatment of these conditions, due to its anti-toxin effect and excellent pharmacokinetic properties in penetrating infected tissues and neutrophils (27) . Patients with such infections are usually too sick to take oral treatment. Injectable clindamycin is needed in our formulary. Macrolides are used as an alternative therapy for patients who are allergic to penicillin and are also the treatment of choice for atypical pneumonia and Legionnaire"s disease. Although atypical pneumonia and Legionnaire"s disease may also be treated with fluoroquinolones, which are available in Sudan, macrolides are preferred because of their safety, low cost and not being associated with collateral damage. Patients may be too sick to take oral treatment and it may be necessary to administer the medicine by intravenous rout. Injectable macrolides should be added to our formulary.
Challenges in the treatment of infections with Gram-negative bacteria in Sudan
The prevalence of ESBL in Enterobacteriaceae is increasing worldwide (28) . This has prompted several centres to reduce the consumption of oxyimino cephalosporins and replace them with β-lactam-β-lactamase inhibitors that are least associated with collateral damage (1,2) . The addition of piperacillin-tazobactam to the hospital formulary at the Cleveland Department of Veterans Affairs Medical Centre and minimizing the administration of ceftazidime were associated with a marked decrease in ceftazidime-resistant isolates (29) . In a similar report, Landman et al demonstrated significant reduction in ceftazidime-resistant Klebsiella pneumoniae by reducing the consumption of ceftazidime and increasing the use of piperacillintazobactam (1) . β-lactam-β-lactamase inhibitors are widely used worldwide. They have broadspectrum activity and are effective against a wide range of pathogens. They cause minimum collateral damage and can be an alternative or compete with the notorious third generation cephalosporins.
Furthermore, piperacillin-tazobactam (piptazo) and ticarcillin-clavulanic acid have activity against Pseudomonas aeruginosa as well as anaerobes. In Sudan, ESBL prevalence is the highest even when compared to neighbouring Arab countries. Sixty percent to 80% of Escherichia coli and Klebsiella pneumoniae isolates in KTH and SUH were ESBL producers, while in Arab countries ESBL prevalence ranged from 6% in Saudi Arabia to 15% in Oman (14, 30) . The available treatment for infections with these organisms in Sudan is meropenem, which is prohibitively expensive for most patients. Furthermore, most laboratories in Sudan do not test for ESBL production and may erroneously report an ESBL producer as sensitive to cephalosporins; as such organisms may appear sensitive on an ordinary disc diffusion test. This may in turn give false impression to the clinicians and mask the true picture of the high prevalence of cephalosporin resistance. Other problem is the emergence of carbapenem-resistant strains with increasing frequency. During the period January 2011 to June 2013, we isolated 80 bacterial strains in SUH resistant to all available antibiotics including meropenem (Microbiology records SUH). Meropenem resistance may be due the notorious metallo-β-lactamases that inactivate all β-lactams except aztreonam. Recently strains of Escherichia coli and Klebsiella spp. carrying genes for this resistance (blaNDM1) originated from the Indian Subcontinent and have spread worldwide (31) . Infections with carbapenem-resistant organisms are treated with colistin (colistimethate sodium) or tigecycline, which, unfortunately, are not available in Sudan. Colistin is a polymyxin, active only against Gram-negative bacteria including carbapenem-resistant strains. Tigecycline is a glycylcycline antibiotic active against a wide range of microorganisms including anaerobes, carbapenem-resistant bacteria, chlamydia and mycoplasma. 
